Literature DB >> 1889877

Combination effect of SCE-2787 and cefepime with aminoglycosides on nosocomial gram-negative bacteria.

J Hübner1, D Hartung, A Kropec, F D Daschner.   

Abstract

The in vitro activity of cefepime and SCE-2787, two new parenteral cephalosporins, and the combination effect with tobramycin and gentamicin against nosocomial gram-negative rods was studied using checkerboard agar dilution technique. Cefepime showed excellent in-vitro activity against Klebsiella pneumoniae, Enterobacter cloacae, Serratia marcescens and Proteus vulgaris (MIC90 0.03-0.125 mg/l) and good to moderate activity against Acinetobacter anitratus, Pseudomonas aeruginosa and Pseudomonas cepacia (MIC90 4-16 mg/l). SCE-2787 had an excellent activity against Citrobacter spp. (MIC90 0.125 mg/l) and a very good activity against A. anitratus, P. aeruginosa and P. vulgaris (MIC90 1-2 mg/l). Pseudomonas maltophilia was not inhibited at therapeutically achievable concentrations (MIC90 64 mg/l). On average, 14-28% of the strains were inhibited by synergistic SCE-2787 aminoglycoside-combinations, whereas only 8.6% were inhibited by a synergistic effect of the combination with cefepime and gentamicin. No antagonism occurred with any of the combinations.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1889877     DOI: 10.1007/bf01643250

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  18 in total

1.  Safety, tolerance, and pharmacokinetic evaluation of cefepime after administration of single intravenous doses.

Authors:  R H Barbhaiya; S T Forgue; C R Gleason; C A Knupp; K A Pittman; D J Weidler; R R Martin
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

2.  In vitro studies of BMY-28142, a new broad-spectrum cephalosporin.

Authors:  G P Bodey; D H Ho; B LeBlanc
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

3.  In vitro activity of fleroxacin and 6 other antimicrobials against Acinetobacter anitratus.

Authors:  A Kropec; F Daschner
Journal:  Chemotherapy       Date:  1989       Impact factor: 2.544

4.  Evaluation of the in vitro activity of BMY-28142, a new broad-spectrum cephalosporin.

Authors:  P C Fuchs; R N Jones; A L Barry; C Thornsberry
Journal:  Antimicrob Agents Chemother       Date:  1985-05       Impact factor: 5.191

5.  Affinity of cephalosporins for beta-lactamases as a factor in antibacterial efficacy.

Authors:  D J Phelps; D D Carlton; C A Farrell; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

6.  Emergence of resistance to ceftazidime during therapy for Enterobacter cloacae infections.

Authors:  J P Quinn; C A DiVincenzo; J Foster
Journal:  J Infect Dis       Date:  1987-05       Impact factor: 5.226

7.  In vitro antibacterial activity of BMY-28142, a new extended-spectrum cephalosporin.

Authors:  A Vuye; J Pijck
Journal:  Antimicrob Agents Chemother       Date:  1985-04       Impact factor: 5.191

8.  Activity of cefepime against ceftazidime- and cefotaxime-resistant gram-negative bacteria and its relationship to beta-lactamase levels.

Authors:  J Fung-Tomc; T J Dougherty; F J DeOrio; V Simich-Jacobson; R E Kessler
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

9.  Comparison of a new cephalosporin, BMY 28142, with other broad-spectrum beta-lactam antibiotics.

Authors:  R E Kessler; M Bies; R E Buck; D R Chisholm; T A Pursiano; Y H Tsai; M Misiek; K E Price; F Leitner
Journal:  Antimicrob Agents Chemother       Date:  1985-02       Impact factor: 5.191

10.  Combination effect of azthreonam with four aminoglycosides on nosocomial gram-positive cocci and non-fermenting gram-negative bacteria.

Authors:  H M Just; E Phillips; M Bassler; F D Daschner
Journal:  Eur J Clin Microbiol       Date:  1982-12       Impact factor: 3.267

View more
  2 in total

Review 1.  Cefepime clinical pharmacokinetics.

Authors:  M P Okamoto; R K Nakahiro; A Chin; A Bedikian
Journal:  Clin Pharmacokinet       Date:  1993-08       Impact factor: 6.447

Review 2.  Versatility of aminoglycosides and prospects for their future.

Authors:  Sergei B Vakulenko; Shahriar Mobashery
Journal:  Clin Microbiol Rev       Date:  2003-07       Impact factor: 26.132

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.